Abstract: Antigenic fragments of human Factor VIII polypeptide, pharmaceutical compositions which contain these fragments, and complexes containing these peptides and a carrier protein or peptide.

Abstract: An antigenic polypeptide of factor VIII comprises a polypeptide included between the Glutamic Acid 1649 and Asparagine 2019, preferably between Arginine 1652 and Arginine 1917 of the polypeptide of factor VIII, or a polypeptide included between Alanine 108 and Methionine 355, or a polypeptide included between Aspartic Acid 403 and Aspartic Acid 725, or a polypeptide included between Lysine 2085 and Lysine 2249.

Abstract: A method and an apparatus for inactivating contaminants in blood products are disclosed. The blood product is flowed past an emitter of type C ultraviolet radiation while controlling the flow of the blood product so that the irradiation doses which are received by the blood product are lower than 640 joules/m2. The blood product is substantially free of nonenveloped viruses after the irradiation. The apparatus includes an emitter of type C ultraviolet radiation placed so as to emit the type C radiation toward the blood product in a quartz tube or a tube made of polymerized material which does not absorb type C radiation. The apparatus also includes a flow meter for controlling the flow rate of the blood product to be treated.

Abstract: The present invention relates to an antigenic polypeptide sequence of factor VIII, comprised between the Glutamic Acid 1649 and Asparagine 2019, preferably comprised between Arginine 1652 and Arginine 1917 of the polypeptide sequence of factor VIII, or comprised between Alanine 108 and Methionine 355, or comprised between Aspartic Acid 403 and Aspartic Acid 725, or comprised between Lysine 2085 and Lysine 2249.

Abstract: The present invention is related to the antigenic polypeptide sequence of Factor VIII.

Abstract: A method and an apparatus for inactivating contaminants in blood products are disclosed. The blood product is flowed past an emitter of type C ultraviolet radiation while controlling the flow of the blood product so that the irradiation doses which are received by the blood product are lower than 640 joules/m2. The blood product is substantially free of nonenveloped viruses after the irradiation. The apparatus includes an emitter of type C ultraviolet radiation placed so as to emit the type C radiation toward the blood product in a quartz tube or a tube made of polymerized material which does not absorb type C radiation. The apparatus also includes a flow meter for controlling the flow rate of the blood product to be treated.

Abstract: A method and apparatus for inactivating contaminants, particularly nonenveloped viruses, in blood products without the need for quenchers in the blood products. The blood product is flowed through a flow meter at a controlled flow rate and subjected to type C ultraviolet radiation, where the irradiation dose received by the blood product is less than 640 joules/m2. The blood product does not contain quenchers when being irradiated, and the blood product retains more than 85% of its Factor VIII activity after being subjected to the radiation. The produced blood product is free of viruses and quenchers, avoiding potential toxicity due to the quenchers. The apparatus includes a source of UVC light, a quartz tube containing the blood product while it is exposed to the UVC light, a flow meter for controlling the flow rate of the blood product to be treated, and a pump. The UV light preferably emits light at 254 nm.

Abstract: The invention synergimicin derivatives having the general formula: Z--X--R, in which Z is a type A or type B synergimycin radical linked by its reactive carbonyl position, through a branch X, where X is .dbd.N-- or .dbd.N--O--, to a substituted R, where R is a hydrogen atom, an alkyl group, an alkyl-COOH group, an -alkyl-(.alpha.NH.sub.2)COOH group (I), group (II), group (III) or a group (IV), where n is a function of the number of --NH.sub.2 groups present on the coupling protein. Also described are the salts, esters and possibly addition products of pharmaceutically acceptable acids. The invention also concerns a process for preparing these substances, and their use.